Policy & Regulation
Cerevel Therapeutics Names Mishan as Chief Business Officer
16 August 2019 - - US-based neuroscience disease treatements developer Cerevel Therapeutics has appointed Orly Mishan as chief business officer, the company said.

In this newly created role, Mishan will lead corporate development, program management, and technical operations while contributing to the advancement of the company's strategy as a member of the executive leadership team.

Mishan joins Cerevel Therapeutics from Bain Capital Life Sciences where she served as principal, overseeing investments in biopharmaceutical, medical device, diagnostics, and enabling technology companies.

She was a founding member of the Bain Capital Life Sciences team and helped execute the partnership with Pfizer that led to the formation of Cerevel Therapeutics.

Prior to joining Bain Capital Life Sciences, Mishan was the vice president of corporate strategy at Biogen.

She spent more than 10 years at Boston Scientific in leadership roles supporting strategy, transaction and restructuring activities, and spearheading the development of the global healthcare services business.

Mishan started her career as a business analyst at McKinsey and company and later helped lead interdisciplinary transaction and product development teams at Pfizer. She earned a Bachelor of Arts in economics and political science from Columbia University.

Cerevel Therapeutics is focused on unraveling the mysteries of the brain to treat neuroscience diseases.

The company is unlocking new treatment opportunities by understanding the neurocircuitry of symptoms.

Cerevel Therapeutics has a diversified pipeline comprising three clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including epilepsy, Parkinson's, Alzheimer's, schizophrenia and addiction.

Headquartered in the Greater Boston area, Cerevel Therapeutics is fueled to advance its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or acquisitions.